The Rise of Direct-to-Patient
Originally appeared on the CSM website. View original
The healthcare industry has changed its focus. The needs of the patient, rather than the needs of the industry, are now at the center of the clinical studies conducted. This patient-centric approach benefits the patient, and ultimately the success and efficiency of clinical trials.
Conducting a trial can be complicated. With patients geographically spread out, in need of frequent doses, and a drug product that has strict storage and delivery conditions, the process is even more difficult. When dealing with homebound patients, an orphan indication, or a dispersed patient population, patient enrollment and retention can be a challenge.
Specialized clinical supplies managers can help a sponsor execute a Direct-to-Patient program to overcome fundamental challenges that prevent the sponsor from conducting a trial. The program, which provides a highly customizable solution per patient and per protocol, helps reduce the number of patient dropouts and the overall cost of a study.
What is Direct-to-Patient?
Direct-to-Patient (DtP) is a patient-centric approach to clinical supplies. Supplies are prepared, packaged, labeled, and then shipped directly to the home of the patient or caregiver. Patients no longer have to visit the clinical site for diagnosis, labs and data collection, which is a challenge for many. As a result, Direct-to-Patient can positively impact patient enrollment and retention. This method also enables sponsors to avoid shipping to, and storing supplies at, clinical sites.
Partnering with an experienced service provider that understands the ins and outs of the method and has the experience and expertise to take advantage of all the opportunities, and manage the challenges, is essential to the successful execution of the Direct-to-Patient model.